Home
Saral Gyan Articles
Saral Gyan Services
Subscription
About Us
Contact Us
Dear Reader,
Most of the pharmaceutical companies have delivered strong top line and bottom line with robust growth during last couple of years. Rupee depreciation and favourable economy in US has helped these companies to deliver strong top line growth with outstanding profits. In this post we would like to discuss a very small cap stock Caplin Point Laboratories (BSE Code – 524742) from the same sector. As mentioned in one of our previous posts, small and micro cap stocks comes with high risk factor, however quick decision making and keeping a strong tab on the performance of such companies can also result in substantial gains.
Most of the pharmaceutical companies have delivered strong top line and bottom line with robust growth during last couple of years. Rupee depreciation and favourable economy in US has helped these companies to deliver strong top line growth with outstanding profits. In this post we would like to discuss a very small cap stock Caplin Point Laboratories (BSE Code – 524742) from the same sector. As mentioned in one of our previous posts, small and micro cap stocks comes with high risk factor, however quick decision making and keeping a strong tab on the performance of such companies can also result in substantial gains.
Company Background:
Caplin
Point is a debt free company with a market cap of 215 crores. The company’s
area of focus is export of generic medicines, vitamins, suppositories
and soft gel capsules to regions such as Latin America, West Africa, and South
East Asia among others. As per the Annual Report, the Company holds over
1300 product registrations in these markets and has tied up with Exclusive
Import and Distribution companies in 25 countries across Latin America, Africa
and S.E Asia.
In
2012 the Company commenced a project for setting up of a state of the art
Injectables plant for catering to highly regulated markets like USA, EU,
Brazil, South Africa etc. The facility is being designed in compliance with
norms stated by USFDA, UK MHRA, ANVISA BRAZIL, EU GMP and other regulatory
bodies and once the facility is operational and gets the regulatory approvals
the company will also start exports to fully regulated markets of USA, Europe,
Mexico and Brazil. From the new facility the Company would also be in a
position to offer Contract manufacturing services in the areas of general
category Injectables dosage forms in Vials, Ampoules, Lyophilized Vials,
Pre-filled syringes and Ophthalmic preparations.
Financial Performance:
As can be observed from the above
illustration, the performance of Caplin Point has improved significantly in the
last 3 years. The sales growth has been good and the operating margins have
expanded from 8-9% a few years back to around 16-17% (if we exclude the impact
of foreign exchange fluctuation loss then operating margins are even higher at
19-20% for H1 FY 14).
What is really interesting about the
performance is really high cash flows (in comparison to reported profits) from
operations. The cash flows have been really good as the company gets advance
payments for exports and the same have resulted in
repayment of entire debt (the company is sitting on surplus cash) and at the
same time carry out a major expansion (~70 crores in comparison to net worth of
56 crores) towards setting up a new manufacturing facility which will serve highly
regulated markets of US, Europe, Brazil, etc.
It’s unusual to find negative working capital
situation (on account of advance payments) in pharmaceutical industry and that
too for such a small company; however it is true in case of Caplin and even the
management acknowledges it as one of their strengths in Annual Report 2013.
Valuations:
At current market cap of 233 crores, Caplin Point is trading at
13.5 times trailing twelve months earnings and considering the growth momentum
probably 10 times FY 14 earnings. The company is debt free with surplus cash
and as illustrated above has decent operating performance history with high
margins, good cash flows and return ratios.
Risks & Concerns:
We have not been
able to establish the reason behind such a vast improvement in performance in
the last few years and if the same is sustainable. Also, as the website does
not provide much detail on the products, the factors helping the company get
advance payments from its customers are not evident.
Note: The stocks discussed in Saral Gyan through posts are not a part of our "Hidden Gems" and Value Picks issue which we recommend to our paid subscribers only. These are just stock specific views by Saral Gyan Team; one must do the due diligence before doing any investment based on our recommendation.
Opportunity missed is an opportunity lost. Subscribe to Hidden Gems (Unexplored Multibagger Small Cap Stocks) and Value Picks (Mid Caps with Plenty of Upside Potential) and start making educated investment decisions by investing in fundamentally strong small and mid cap companies. Click here to know more about our services and annual subscription charges.
